Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety, tolerability and progression-free
survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in
combination with docetaxel and prednisone.